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Cardiovascular disease is the leading cause of death and disability worldwide. Recent work 24 
suggests a link between vitamin K insufficiency and deficiency with vascular calcification, a 25 
marker of advanced atherosclerosis. Vitamin K refers to a group of fat-soluble vitamins 26 
important for blood coagulation, reducing inflammation, regulating blood calcium metabolism, 27 
as well as bone metabolism, all of which may play a role in promoting cardiovascular health. 28 
Presently, there is a lack of a comprehensive vitamin K database on individual foods, which 29 
are required to accurately calculate vitamin K1 and K2 intake for examination in 30 
epidemiological studies. This has likely contributed to ambiguity regarding the recommended 31 
daily intake of vitamin K, including whether vitamin K1 and K2 may have separate, partly 32 
overlapping functions. This review will discuss the presence of: (i) vitamin K1 and K2 in the 33 
diet; (ii) the methods of quantitating vitamin K compounds in foods; and (iii) provide an 34 
overview of the evidence for the cardiovascular health benefits of vitamin K in observational 35 
and clinical trials. 36 
Key words 37 






Vitamin K refers to a group of fat-soluble vitamins important for blood coagulation and has 42 
been linked to other biological processes including blood calcium metabolism, as well as bone 43 
and vascular health.1 The two main vitamin K forms are vitamin K1 (phylloquinone; PK) and 44 
vitamin K2 (menaquinones; MK). The few studies that have explored the link between vitamin 45 
K1 and/or K2 with cardiovascular outcomes have reported conflicting results.1 Despite the 46 
potential importance of vitamin K1 and/or K2 for human health, the adequate intake (AI) 47 
recommendations proposed by numerous public health organisations typically only consider 48 
vitamin K1. This is likely a result of limited information relating to vitamin K2.2 Specifically, 49 
there is currently a lack of international comprehensive databases on the vitamin K content of 50 
individual foods, which are required to accurately calculate vitamin K1 and/or K2 intake.2 This 51 
review discusses the: (i) presence of vitamin K1 and K2 in the diet; (ii) the methods of 52 
quantitating vitamin K compounds in foods; and (iii) provides an overview of the evidence for 53 
the cardiovascular health benefits of vitamin K in observational and clinical trials. We also 54 
propose that the development of a comprehensive national vitamin K databases of individual 55 
food items is critical to advance our understanding of vitamin K nutrition for a range of health 56 
outcomes including cardiovascular health.  57 
Vitamin K: phylloquinone and menaquinones  58 
Vitamin K is a group of structurally and functionally analogous fat-soluble vitamins, which act 59 
as cofactors in the post-translational γ-carboxylation of vitamin K-dependant proteins (VKDP). 60 
Vitamin K compounds are characterised by a 2-methyl-1,4-naphthoquinone backbone also 61 
called menadione and a lipophilic isoprenoid side chain attached at carbon three (Figure 1). 62 
Two types of vitamin K exist naturally: vitamin K1 (PK) and vitamin K2 (MK).3 Phylloquinone 63 
has a side chain analogous to the phytyl side chain of chlorophyll; four isoprenoid residues of 64 
which three are saturated. It is synthesised by all photosynthetic plants and algae, as it is a 65 
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functional component in photosynthesis.4 Vitamin K2 (MK) is composed of a group of 66 
isoprenologs where the side chain is a polymer of isoprenoid units ranging between four to 67 
thirteen repeats. MKs are named according to the number of repeating units,4 with derivatives 68 
including MK-4 to MK-13. For example, MK-4 has four unsaturated isoprenoid units (Figure 69 
1). Despite having analogous structures the origins of MKs differ. MK-4 is synthesised from 70 
PK and menadione by animals and humans.2 All other MKs are synthesised by anaerobic 71 
bacteria, which includes species present in the human microbiome.4 Bacterial MKs are 72 
important in metabolic respiration acting as components of the electron transport chain.5 The 73 
synthetic compound, menadione, is also referred to as vitamin K3 and is often added to animal 74 
feed.6 75 
Dietary vitamin K 76 
Phylloquinone is present in the majority of foods including vegetables, fruits, nuts, bread, 77 
cereals, oil, meat and animal products; however, quantities vary greatly.7, 8 The highest 78 
concentrations of PK found in green leafy vegetables, due to its role in photosynthesis. 79 
Concentrations in these vegetables range between 400-700 µg/100 g.4 Vegetable oils, such as 80 
olive, canola and soybean, also contain considerable amounts of PK. These oils are widely used 81 
in margarine, salad dressings, and the preparation of foods, such as bread. The contribution of 82 
oils as part of commercially consumed foods towards total dietary vitamin K intake may be 83 
greater than initially thought. For example, in the US, commercially prepared foods and mixed 84 
dishes were the second highest contributors to PK intake, after vegetables.9 The widespread 85 
use of plant products in food production and their consumption by animals explains the 86 
presence of PK in disparate food groups. The PK content in the Western diet makes up the 87 
majority of vitamin K intake. It constitutes up to 90% of dietary vitamin K intake, of which 60-88 
80% is derived from vegetables.4, 10, 11  89 
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Menaquinones are found in meat, dairy and fermented foods.2 MK-4 is synthesised by the 90 
conversion of consumed PK or menadione in human or animal tissues. Therefore, dietary MK-91 
4 is typically found in animal tissue and products, such as eggs or dairy.2 The tissue or organ 92 
of an animal, the type of animal and country of origin (possibly related to feed) all affects the 93 
MK-4 content in food products.2 For example, goose liver is a major storage tissue of vitamin 94 
K compounds and has the highest MK-4 content of any tissue (370 µg/100 g).3 In comparison, 95 
goose leg has only 60 µg/100 g of MK-4.3 Alternatively, chicken breast has more MK-4 than 96 
duck breast; 8.9 vs 3.6 µg/100 g, respectively.3 Poultry and pork, have especially high MK-4 97 
content due to menadione in their feed, which is converted into MK-4.2, 12 The MK-4 content 98 
of various poultry products vary greatly.2 Presently, the most comprehensive tool to calculate 99 
the MK-4 content of food is provided by the United States Department of Agriculture (USDA) 100 
Food Composition Databases.13 However, there is limited information on the MK-4 content in 101 
some commonly consumed meats, such as lamb, veal, and goat.14 Other MKs (MK5-12) are 102 
synthesised by anaerobic bacteria4; however, information on their approximate content in food 103 
products are scarce.   104 
Foods fermented with the MK-synthesising bacteria are abundant in long-chain MKs. For 105 
example, natto (fermented soybeans) has been reported to have the highest MK-7 content of 106 
any food, containing 936 µg/100 g.15 The type of MKs produced is dependent on the type of 107 
bacteria and temperature conditions.5 Notably, bacteria that produce MK-9 also produce MK-108 
8, but in four-fold lower amounts. Thus, MK-9 and MK-8 co-occur in foods that are fermented. 109 
Other MKs are produced independent of each other.16 Not all fermented foods contain MKs. 110 
For example, yeast has lost the enzymes required for MK synthesis,4, 5 thus bread does not 111 
contain MKs.2 Fermented dairy products, such as cheese, milk and yogurt, are significant 112 
sources of long-chain MKs.2, 17 The MK content varies by the percentage of fat present in dairy. 113 
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For example, the MK content of full fat cheddar cheese is five times higher than the total MK 114 
content of reduced-fat cheddar (281 µg/100 g vs. 49 µg/100 g, respectively).17 115 
Few studies have analysed the MK content in the Western diet. From this limited work, MKs 116 
have been reported to constitute approximately 10% of dietary vitamin K intake.4, 10, 11 Of note, 117 
the major MK form is MK-4, which contributes 25-40% of the total MK in the diet.10, 11 After 118 
MK-4, the most nutritionally abundant MKs are MK-9, MK-8 and MK-7.10, 18 However, as the 119 
MK content in individual foods has not been systematically determined to the degree of PK,2 120 
this may lead to errors in these estimates. Studies have highlighted meat and dairy products as 121 
the best sources of MKs.3 For example, a German study reported that 60% of all MKs came 122 
from dairy products, with cheese consumption contributing 43% of total MK intake.10 123 
Considering, the European diet is typically rich in cheese, it is thought to be a major contributor 124 
of MK intake in such populations.2 Presently, the most comprehensive resources for the 125 
different MK content from a variety of animal and plant-based foods is from the Netherlands.3 126 
Besides the aforementioned Dutch work, there is relatively little data for the MK content in the 127 
diets of other countries. This is likely due to the absence of comprehensive databases of MK 128 
content in individual foods, which are required to quantify MK intake at individual and 129 
population levels.2 130 
Bioavailability of vitamin K  131 
Bioavailability is the rate and extent by which a nutrient is absorbed and becomes available to 132 
the target tissue.19 Alternatively, bioaccessibility relates to the amount of compound that is 133 
released from its matrix in the gastrointestinal tract and is available for absorption.19 Precise 134 
quantitative assessments of vitamin K bioavailability in humans is challenging due to 135 
unquantified tissue conversion of PK to MK-4 and the contributions of the gut microbiota.20 136 
Both PK and MKs are absorbed from the intestine using the same mechanisms as other fat 137 
soluble vitamins and lipids.4 Apart from this shared absorption mechanism there are differences 138 
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in the bioavailability and bioaccessibility of vitamin K compounds.3 For example, previous 139 
work examining the absorption rate of PK and MK in a food matrix reported that MK 140 
absorption from natto (Japanese fermeneted soybean) is approximately 10 times greater 141 
compared to PK absorption from spinach. Of note, peak serum values for both PK and MK 142 
appear to occur at the ~6 h post-prandial mark. It was also reported that bioavailability of PK 143 
from foods is significantly reduced by its poor bioaccessibility from the food matrix.3 144 
Specifically, only 5-10% of PK is absorbed from cooked vegetables; however, this can be 145 
increased slightly by the presence of dietary lipids.3 In contrast, PK absorption from oils and 146 
supplements have much higher absorption rates (~200-400%) compared to vegetables.3, 21, 22 147 
This indicates that PK as a nutrient can be well absorbed, but the vegetable food matrix may 148 
present a barrier to absorption. Compared to PK, the limited amount of studies conducted on 149 
long-chain MKs suggest they may have higher bioaccessibility from dietary sources3. 150 
Specifically, the absorption of long-chain MKs (MK-7, MK-8 and MK-9) from natto, cheese 151 
and egg yolk is close to 100%.3 Furthermore, these long-chain MKs have a longer half-life. For 152 
example, in a study where 6 male volunteers were given 2 μmol of PK, MK-4 and MK-9, MK-153 
9 was still detectable in the serum at 48 h, while PK and MK-4 returned to baseline after 24 154 
h.23 Notably, the long half-life of MK-9 may not necessarily indicate increased bioavailability, 155 
but instead non-preferential utilisation by tissues compared to PK and MK-4. A long half-life 156 
may also indicate that long-chain MKs may be of particular importance for extrahepatic 157 
tissues.24 Despite the aforementioned work, the bioavailability of vitamin K compounds from 158 
different food matrixes remain largely unknown. Nevertheless, current evidence suggest that 159 
long-chain MKs may be more important than previously thought for vitamin K status, due to 160 
the almost complete absorption of long-chain MKs and poor absorption of PKs from its main 161 




Non-dietary sources of menaquinones  164 
Despite, the large proportion of animal-based foods known to contain MKs, not all of the MKs 165 
come from dietary sources. There are two known alternative sources, including PK conversion 166 
into MK-4, and MK synthesis by the gut microbiota.4, 26 The full extent of the conversion of 167 
PK to MK-4 is unknown, but in the last decade progress has been made in understanding the 168 
mechanism. Specifically, intestinal PK is cleaved in enterocytes to produce menadione (often 169 
referred to as vitamin K3), which is prenylated by UbiA prenyltransferase-containing domain 170 
1 (UBIAD1) to produce MK-4.4, 26 A recent study in rats demonstrated that only 0.1% of oral 171 
PK was converted into MK-4, and 2% converted into menadione.27 The extent of this 172 
conversion in humans remains unclear, but it is estimated to be 5-25% of PK intake.28 173 
Therefore, MK-4 biosynthesis from PK may be a large source of MKs, but detailed human 174 
studies are needed to examine this further. In addition, the contribution of microbial-175 
synthesised MKs to human nutrition is not fully understood. The majority of MKs in the gut 176 
are synthesised by Bacteroides-one of the largest intestinal genera.29, 30 Bacteroides primarily 177 
produce MK-10 and MK-11, with small amounts of MK-7 to MK-9.29, 31 There is a large pool 178 
of MKs in the gut, with previous work suggesting an average of 1.8 mg of vitamin K2 in the 179 
intestinal tract of humans.32 Despite such reserves of vitamin K2 being over 20 times the AI 180 
for adult males, the bioavailability of these MKs is thought to be limited.33 Specifically, vitamin 181 
K compounds are absorbed in the small intestine in a process requiring bile salts and pancreatic 182 
enzymes, which are absent where the majority of bacteria colonise the colon.34 Additionally, 183 
the majority of microbial-synthesized MKs are bound by bacterial membranes and thus are not 184 
available for absorption.2 Therefore, while a large amount of MKs are produced by the gut 185 
microbiota, their poor bioavailability at the point of synthesis limits their contribution to human 186 
vitamin K nutrition.31, 33 Presently, the exact bioavailability of microbial-synthesised MKs is 187 
unknown, and more bioavailability studies are required to discern their role in human nutrition. 188 
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Dietary recommendations for vitamin K 189 
Current dietary vitamin K recommendations are typically based on the intake of PK sufficient 190 
to maintain coagulation.20 This is problematic as the tissue-requirements of extrahepatic 191 
vitamin K-dependant proteins for PK differs from the requirement of hepatic vitamin K-192 
dependant proteins.2 Therefore, dietary intakes which are sufficient to maintain coagulation 193 
may be inadequate in optimising other aspects of health that might be impacted by vitamin K 194 
nutrition.2, 28 However, any attempts to update the AI values for vitamin K1 or include vitamin 195 
K2 would be hampered by a lack of dose-response studies and evidence on the occurrence, 196 
absorption, function and content of MKs in the body or organs.28, 35, 36 Difficulties in 197 
quantitating the contribution of MKs synthesised by the gut microflora and tissue conversion 198 
of PK are additional challenges when defining dietary requirement.20 Furthermore, a recent 199 
report by the European Commission highlighted the uncertainties in country-wide estimates of 200 
vitamin intake data, which are caused by ‘borrowing’ vitamin K values from other countries 201 
and substituting vitamin K values for individual food items for similar foods or food groups.35 202 
For example, the USDA database13 which was used to determine the vitamin K Nutrient 203 
Reference Values for Australia and New Zealand.37 Presently, the AI for vitamin K intake is 204 
set at 60 and 70 µg/d for adult Australian females and males respectively.37 Alternatively, it 205 
has been proposed that even intakes of 90-120 µg/day (set by the USDA)13 of vitamin K may 206 
not be sufficient to induce complete carboxylation of all VKDPs.38 Consequently, AI 207 
recommendations in Australia for vitamin K intake may not accurately reflect actual vitamin 208 
K intake (or demands), and may lead to ambiguity when determining optimal vitamin K 209 
nutrition. There is a need for both the development of regional databases and the expansion of 210 
existing databases to include both vitamin K1 and K2 content (including a range of MKs) in 211 
commonly consumed foods. Such work will allow for improvements in the determination of 212 
dietary vitamin K recommendations. Finally, due to differences in the bioavailability and/or 213 
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bioaccessibility of vitamin K2, future guidelines may need to consider distinguishing between 214 
dietary vitamin K1 and K2. 215 
Vitamin K databases 216 
Databases of nutrients allow for the calculation of individual and population level intake of 217 
nutrients, permitting for epidemiological investigation. Although there appears to be ~70 218 
sources containing information relating to the vitamin K content of food, closer analysis of 219 
these reveal that current databases are largely incomplete.25 Specifically, only 12 databases list 220 
the vitamin K content of individual food items, which is required to more accurately determine 221 
vitamin K intake.25 The Dutch database is the most comprehensive and includes PK and several 222 
types of MKs, ranging from MK-4 to MK-10.39 Although the largest database (in English) has 223 
been developed by the USDA, this database does have limitations. Specifically, food items 224 
have only been assessed for PK and MK-4 in the 25th release of the USDA database.13 225 
Considering no other MKs have been included in the database, this limits its utility for 226 
accurately estimating total vitamin K2 intake. The USDA database also lacks some commonly 227 
consumed animal products, including lamb, veal and goat, which are potentially rich sources 228 
of MKs.13 The limited availability of comprehensive, national databases that lists both PK and 229 
MK content in food hampers investigation of the relationship between dietary vitamin K1 230 
and/or K2 intake and a range of health outcomes. Nevertheless, available databases provide 231 
researchers with an indication of the types of food that are rich in vitamin K1 and K2 (including 232 
the specific MKs). By reviewing pre-existing databases,3, 13, 15, 17, 39, 40 we have compiled a list 233 
of commonly consumed foods and their approximate vitamin K content in Table 1. However, 234 
estimates of the respective vitamin K1 and K2 content of the foods listed in Table 1 should be 235 





Regional differences in the vitamin K content of food 239 
The content of both PK and MKs in foods are known to differ between regions.2 For example, 240 
beef cuts in Japan contain more MK-4 than the United States (15.0 ± 7.0 vs. 1.1 to 9.3 µg/100 241 
g, respectfully).14, 15 Similarly, the MK-4 content in egg yolk is four times higher in Japan 242 
compared to the United States (64 vs 15.5 µg/100g).2 The variability in MK-4 has been 243 
attributed to the use of menadione in animal feeds and further differences in food production.2 244 
Variability of up to 15% has been reported in the MK content (MK-6 to MK-10) of semi-hard 245 
cheese varieties in three different European countries (France, Poland, Denmark).16 246 
Furthermore, intra-country MK variability can be high (up to 80%), as reported between six 247 
English cheddar cheeses.16 Results are also complicated by a range of methodologies 248 
(discussed in subsequent section) used to quantify PK and MKs. The regional differences in 249 
food production, climate conditions, and dietary consumption patterns highlights the 250 
importance of comprehensive and detailed databases that are population specific. Ideally, 251 
databases should include information relating to the brand, type, method of creation and region 252 
of grown foods alongside their PK and MK content. If regional differences in vitamin K content 253 
of food are ignored, this can lead to inaccuracies when estimating vitamin K intake. Although 254 
the investment in comprehensive databases is unlikely to occur in most countries, the creation 255 
of more region specific databases on the vitamin K contents of foods would ultimately facilitate 256 
better estimation of vitamin K1 and K2 intake.   257 
Measuring dietary vitamin K  258 
Methods to quantitate phylloquinone and menaquinones in food 259 
To develop databases, a validated method of measuring PK and MKs simultaneously, with 260 
accuracy and high throughput, is required. These methods must have high sensitivity and 261 
selectivity due to the low vitamin K content in foods, and the complexity of the food matrix.41 262 
A recent review concisely summarised quantification methods for determination of vitamin K 263 
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in various biological matrices including blood, urine and tissue.42 However, the quantification 264 
of vitamin K from food were not considered in detail. Existing methods to determine PK and 265 
MK levels from food generally use reverse-phase HPLC with fluorescent detection or HPLC–266 
Mass Spectrometry (MS), with K1 or deuterated-K1 as the internal standard, respectively.16, 43 267 
Gas Chromatography-MS (GC-MS) has also been used with deuterium-labelled internal 268 
standards to accurately measure PK in serum.44, 45 However, there are limitations in using GC 269 
for measuring vitamin K, as high temperatures are needed to volatise vitamin K compounds 270 
(>300°C).46 Therefore, HPLC is the preferred method to separate vitamin K compounds for 271 
analysis.41 The emerging method to measure vitamin K in foods is a HPLC-MS method 272 
developed by Karl et al.43 This method has high versatility and may be used to measure PK and 273 
all MKs in a variety of forms such as food, serum and faeces.43 Based on current evidence, 274 
HPLC-MS appears to be the best method to measure vitamin K compounds from foods. 275 
Methods of extracting vitamin K from the food matrix 276 
Vitamin K compounds are trapped in the matrix of foods and must be liberated in order to be 277 
accurately measured.3 Vitamin K compounds are unstable in alkali conditions and undergo 278 
photo-oxidation upon exposure to ultraviolet light, which limits the available extraction 279 
methods.46 Samples must be stored in amber vials and all work done yellow light to prevent 280 
this degradation.43 Due to these limitations, the most common extraction method is liquid-281 
liquid extraction, with the exact process depending on the food matrix.46, 47 Sample pre-282 
treatment is important to liberate K vitamers from the matrix. Most food groups, with the 283 
exception of vegetable oils, are homogenised and sonicated to break up the food matrix.3, 48 284 
This is especially important for vegetables, as it is essential to liberate PK from the thylakoid 285 
membranes.46 Furthermore, some fatty foods, such as oils or cheeses, undergo lipase digestion 286 
or acid treatment to break down fats, thereby increasing purity.16, 46 To our knowledge, there is 287 
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currently no standardised method for the extraction of vitamin K compounds from food, 288 
however, numerous validated methods exist.3, 43, 47 289 
Vitamin K and cardiovascular health 290 
Atherosclerotic cardiovascular disease  291 
Cardiovascular disease accounts for approximately 1 in 3 deaths worldwide.49 Atherosclerotic 292 
cardiovascular disease includes coronary heart disease (CHD), peripheral arterial disease and 293 
cerebrovascular disease. Atherosclerotic diseases are caused by endothelial dysfunction, 294 
inflammation and  the slow build-up of cholesterol, fats and calcium deposits forming plaques 295 
in arterial walls.50 The plaques decrease lumen area of the artery, increasing resistance to blood 296 
flow. Vulnerable plaques can rupture or erode leading to blood clots, which can obstruct blood 297 
flow to the heart causing a heart attack, or to the brain causing a stoke. These plaques frequently 298 
develop calcium mineral deposits, which further adds to plaque volume and leads to reduced 299 
arterial compliance leading to an increased risk of organ damage.50 As such, strategies capable 300 
of preventing or delaying the progression of atherosclerosis are fundamental to improving 301 
cardiovascular health. 302 
Vitamin K and vascular calcification 303 
The arterial (vascular) calcification process was once thought to be passive and a natural 304 
consequence of ageing. However, it is now understood to be a complex biomineralisation 305 
process which is actively regulated.51 Observational studies have reported that vitamin K intake 306 
is inversely associated with arterial calcification.52 The best evidence for a causal role for 307 
vitamin K in arterial calcification comes from vitamin K antagonists (VKA), genetic studies 308 
and short-term randomised controlled trials.52-54 VKA such as warfarin are anticoagulants used 309 
to prevent thrombosis and pulmonary emboli. VKAs reduce the bioactivation of the hepatic 310 
VKDP, such as prothrombin, which contributes to coagulation.55 However, their effects are 311 
non-specific and systemic, thus extrahepatic VKDP are inactivated during VKA treatment.54, 312 
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56 This includes Matrix-Gla Protein (MGP), an inhibitor of arterial calcification,57 activated 313 
protein-C an inhibitor of inflammation and endothelial cell apoptosis,58 and osteocalcin that 314 
may regulate metabolic dysfunction and arterial calcification.59  Studies have shown that the 315 
long-term use of VKA is associated with accelerated arterial calcification.2, 60 VKDPs have 316 
high affinity for calcium-based matrices through their Gla residues58 and the potential role of 317 
vitamin K in enhancing/activating anti-calcification processes (especially through MGP) has 318 
gained much interest.1 However, a fine balance may exist as anti-thrombotic blocking agents 319 
of vitamin K on blood coagulation are an important treatment for preventing heart attacks and 320 
strokes. Although controversial, this has led to suggestions that individuals on anti-coagulants 321 
should consider avoiding vitamin K rich foods.61, 62 322 
MGPs ability to reduce arterial calcification has been demonstrated in MGP knockout mice, 323 
which rapidly develop severe calcification and die from blood-vessel rupture.63 Additionally, 324 
patients suffering from Keutel syndrome, where mutations to the MGP gene render the protein 325 
non-functional,64 also develop extensive soft tissue calcification.65 Polymorphisms within the 326 
MGP have been associated with both atherosclerosis and vascular calcification.53, 66 As 327 
summarised in Figure 2, these results suggest that VKDP, and in particular MGP, may play a 328 
pivotal role in preventing vascular calcification in humans. As a result of the aforementioned 329 
work, the importance of vitamin K for cardiovascular health has recently been investigated in 330 
several observational studies and clinical trials.  331 
Observational studies of vitamin K intake and clinical cardiovascular disease 332 
To date, there are few prospective studies investigating the role of dietary vitamin K intake on 333 
the risk of CVD. These studies are particularly challenging as most databases have very limited 334 
data on the MK content in food, presenting a significant limitation. Likewise, PK intake is 335 
susceptible to social bias, because vegetable intake is generally over-reported, and is likely to 336 
be influenced by variation in vegetable intake across populations.67 Validating the FFQs used 337 
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to estimate vitamin K2 intake is also challenging, as MKs are not typically detected in the 338 
circulation unless large quantities of MK-rich foods are consumed.68 Furthermore, dietary PK 339 
is likely to be influenced by variation in vegetable intake across populations. The Rotterdam 340 
Study (n= 4807), one of the largest investigations to date, found that the relative risk (RR) of 341 
CHD mortality was reduced for individuals within the middle (21.6–32.7 µg/d) and upper 342 
(>32.7 µg/d) tertiles (RR 0.73 95%CI: 0.45-1.17 and RR 0.43 95%CI 0.24-0.77, respectively) 343 
compared to the lowest tertile (<21.6 µg/d) of vitamin K2 intake. Similarly, individuals in the 344 
highest tertile of vitamin K2 intake had lower odds (OR 0.48 95%CI 0.32-0.71) for severe 345 
aortic calcification compared to individuals in the lowest tertile of vitamin K2 intake.69 Of 346 
interest, in the Rotterdam study vitamin K1 intake was not related to CHD. However, this was 347 
based on 233 events and there was a statistically non-significant 11% lower relative hazard 348 
(HR 0.89 95%CI 0.63-1.25) for individuals with the highest intake of PK.69 Noteworthy, this 349 
data should be interpreted with caution as the reproducibility and validity of the FFQ used in 350 
the Rotterdam study for estimating vitamin K intake has been reported to be problematic.70 The 351 
finding that higher dietary K2 is inversely related (per 10 µg/d, HR 0.91 95%CI 0.85-1.00) to 352 
incident CHD has been replicated in the Prospect-EPIC cohort of 16,057 women (aged 49–70 353 
years) free of cardiovascular diseases at baseline.71 This protective affect was attributed 354 
predominantly to long-chain vitamin K2 subtypes MK-7, MK-8 and MK-9.71  355 
Higher dietary MK intake (per 10 µg/d) has also been associated with an 8% decrease in the 356 
relative hazard (HR 0.92 95%CI 0.85-0.99) for peripheral arterial disease (PAD) in 36,629 357 
Dutch individuals form the Prospect-EPIC and MORGEN-EPIC cohorts.72 In contrast, some 358 
studies have reported no association between vitamin K2 intake and CVD mortality or stroke.73-359 
75 It should be noted that the majority of these observational studies have been performed in 360 
the Netherlands; likely due to the Dutch having one of the most comprehensive databases for 361 
vitamin K (especially K2) content in food.69 In contrast to MKs, high PK intake has not been 362 
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associated with CVD mortality,73 CHD incidence and mortality69, 71, 73, 76, 77and PAD72. 363 
However, in two studies where inverse associations between PK intake and CHD incidence 364 
were identified, this relationship was attenuated once other dietary factors were considered.76, 365 
77 This suggests that other components of the diet may also be contributing to observed 366 
findings, and that the healthy dietary patterns associated with high PK intake may at least 367 
partially explain any relationship with reduced CHD risk, rather than PK itself.76, 77 Similarly, 368 
studies examining the link between MK and CHD may be influenced by other components in 369 
MK-rich foods (e.g. saturated fats and sodium from processed meats) associated with CHD. 370 
Additionally, the lack of comprehensive databases for vitamin K1 and K2, and more 371 
specifically the long-chain MK (e.g. MK-5 to MK-13) content of commonly consumed foods 372 
limits our understanding of the role of vitamin K on vascular ageing and clinical cardiovascular 373 
events. As such, caution needs to be exercised when interpreting epidemiological studies of 374 
vitamin K with CHD outcomes. 375 
Vitamin K supplementation trials with surrogate vascular outcomes 376 
To our knowledge, no RCT have examined the effects of vitamin K (e.g. non-pharmaceutical) 377 
on clinical CVD outcomes. Here we discuss the evidence from RCTs investigating surrogate 378 
vascular outcomes such as coronary artery calcification (CAC), arterial stiffness and aortic 379 
valve calcification (AVC). A short 8-week open-label single-arm trial in renal transplant 380 
patients (n= 60) reported a significant decrease in arterial stiffness and 14.2% reduction in 381 
mean carotid femoral pulse wave velocity with higher doses (360 µg/day) of MK-7 382 
supplementation. Of interest, the most benefit was gained in patients presenting with a vitamin 383 
K deficiency (undercarboxylated-MGP >500 pmol/L) at baseline.78 Similar findings were 384 
reported in a separate single arm study that supplemented individuals (n=26, with at least one 385 
coronary risk factor) with 45 µg/day of MK-4 for one year. Specifically, reduced arterial 386 
stiffness (but no changes on CAC) were recorded only in the subset of vitamin K deficient  387 
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patients (n=4).79 The aforementioned work indicate that the vitamin K status of populations 388 
need to be considered when examining potential beneficial of vitamin K for vascular outcomes. 389 
A double blind, placebo-controlled trial found MK-7 supplementation (180 µg/d) over three 390 
years reduced arterial stiffness in 244 healthy post-menopausal women. Furthermore, in 391 
women with higher arterial stiffness (stiffness index β scores ≥10.8) at baseline, improvements 392 
in local carotid pulse wave velocity were recorded, suggesting better elasticity.80 Contrary to 393 
the aforementioned positive findings, a recent double blind, placebo-controlled trial 394 
supplementing MK-7 (360 µg/d) over 6 months in older individuals (~69 y, 24% female) with 395 
type II diabetes and CVD found no significant reduction in femoral arterial calcification 396 
measured by sodium fluoride positron emission tomography.81 397 
To date, few trials have used PK supplements and tracked cardiovascular outcomes.72 An open-398 
label randomised placebo controlled trial of 72 (82% male, mean age 69 years) individuals 399 
reported that 12 months of high dose PK supplementation (2 mg/d) in patients with 400 
asymptomatic or mildly symptomatic aortic valve calcification (AVC) reduced AVC 401 
progression by ~12%.82 Another 3-year double-blind placebo controlled trial examined the 402 
effect of a multivitamin supplement with 500 µg/d of PK (n=200) vs. an identical multivitamin 403 
supplement without PK (n=188) provided in healthy post-menopausal women and men.83 In 404 
participants with high adherence to the supplements (≥ 85%, n=367), there was less CAC 405 
progression in the PK group than in the control group. Furthermore, in individuals with pre-406 
existing CAC (Agatston score >10), those supplemented with PK had 6% less CAC 407 
progression. A randomised placebo controlled trial in postmenopausal women (n=150) 408 
receiving a supplement containing PK (1 mg/day) and vitamin D for 3 years demonstrated 409 
better carotid artery compliance and elasticity, measured by ultrasound of the common carotid 410 
artery.84 Specifically, when comparing the vitamin K and D supplemented group to the placebo 411 
group, better arterial compliance coefficient (8.6%), distensibility coefficient (8.8%), and pulse 412 
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pressure (6.3%) were recorded. Collectively, these large population studies and RCTs suggest 413 
that vitamin K (PK and/or MKs) supplementation may play a vital role in blood vessel health. 414 
An important consideration for future work is to examine if the aforementioned cardiovascular 415 
health benefits observed after PK and/or MK supplementation may be limited only to 416 
populations presenting with vitamin K insufficiency and/or deficiency.  417 
Conclusion 418 
Until recently, a large proportion of research into vitamin K often only considered PK, with 419 
the role of MKs remaining largely ambiguous. It is still unclear as to what the most appropriate 420 
dietary recommendations for daily vitamin K should be, including if a differentiation between 421 
vitamin K1 and K2 need to be considered in nutritional guidelines promoted by public health 422 
organisations. Due to difficulties in the measurement of vitamin K2, the MK derivatives have 423 
also not been extensively tested for basic pharmacokinetic data or their concentration in 424 
numerous food items. Presently, epidemiological data suggest that high dietary MK intake may 425 
be protective against CHD mortality and coronary artery calcification.69 However, the bulk of 426 
evidence for health benefits are limited to the Netherlands; as it currently possesses the most 427 
comprehensive vitamin K database, particularly for MKs. Therefore, observational studies are 428 
still needed to examine these findings in countries with different dietary patterns. There is also 429 
limited evidence from RCTs highlighting the benefit of PK supplements in regards to delaying 430 
the progression of CAC, and improving carotid artery compliance.52, 84 Further investigation 431 
using vitamin K supplementation and its effect on clinical outcomes are still needed. 432 
Unfortunately, current research relating to vitamin K is hampered by the absence of 433 
comprehensive national databases that list both PK and MK content in food. However, with 434 
recent advances in the measurement of PK and MKs using HPLC-MS,43 this could lead to the 435 
development of comprehensive region-specific vitamin K databases. This is especially 436 
important as regional variability in vitamin K content in food may limit the use of out of region 437 
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vitamin K databases.2 Such work will also enable future investigations to explore the potential 438 
importance of dietary PK and MKs (separately or collectively) intake for a range of health 439 
outcomes. The application of these databases to large cohort studies will advance our 440 
understanding of the importance of vitamin K for human health, especially in the 441 
cardiovascular field. This will inform well design RCTs to establish causal effects between 442 
dietary vitamin K and a range of health outcomes. 443 
Conflicts of interest 444 
There are no conflicts of interest to declare. 445 
Acknowledgements  446 
The salary of JMH and JRL was supported by a National Health and Medical Research Council 447 
of Australia Senior Research Fellowship (ID: 1116973) and Development Fellowship (ID: 448 





1. J. J. DiNicolantonio, J. Bhutani and J. H. O'Keefe, The health benefits of vitamin K, 452 
Open Heart, 2015, 2, DOI: 10.1136/openhrt-2015-000300. 453 
2. B. Walther, J. P. Karl, S. L. Booth and P. Boyaval, Menaquinones, bacteria, and the 454 
food supply: the relevance of dairy and fermented food products to vitamin K 455 
requirements, Adv. Nutr., 2013, 4, 463-473. 456 
3. L. J. Schurgers and C. Vermeer, Determination of phylloquinone and menaquinones 457 
in food, Pathophysiol. Haemost. Thromb., 2000, 30, 298-307. 458 
4. M. J. Shearer and P. Newman, Recent trends in the metabolism and cell biology of 459 
vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis, J. 460 
Lipid Res., 2014, 55, 345-362. 461 
5. B. Nowicka and J. Kruk, Occurrence, biosynthesis and function of isoprenoid 462 
quinones, Biochim. Biophys. Acta, 2010, 1797, 1587-1605. 463 
6. G. Lippi and M. Franchini, Vitamin K in neonates: facts and myths, Blood Transfus., 464 
2011, 9, 4-9. 465 
7. C. W. Thane, A. A. Paul, C. J. Bates, C. Bolton-Smith, A. Prentice and M. J. Shearer, 466 
Intake and sources of phylloquinone (vitamin K1): variation with socio-demographic 467 
and lifestyle factors in a national sample of british elderly people, Br. J. Nutr., 2002, 468 
87, 605-613. 469 
8. C. Bolton-Smith, R. J. G. Price, S. T. Fenton, D. J. Harrington and M. J. Shearer, 470 
Compilation of a provisional UK database for the phylloquinone (vitamin K1) content 471 
of foods, Br. J. Nutr., 2007, 83, 389-399. 472 
9. S. G. Harshman, E. G. Finnan, K. J. Barger, R. L. Bailey, D. B. Haytowitz, C. H. 473 
Gilhooly and S. L. Booth, Vegetables and mixed dishes are top contributors to 474 
phylloquinone intake in US adults: Data from the 2011-2012 NHANES, J. Nutr., 475 
2017, 147, 1308-1313. 476 
10. K. Nimptsch, S. Rohrmann and J. Linseisen, Dietary intake of vitamin K and risk of 477 
prostate cancer in the heidelberg cohort of the european prospective investigation into 478 
cancer and nutrition (EPIC-Heidelberg), Am. J. Clin. Nutr., 2008, 87, 985-992. 479 
11. L. J. Schurgers, J. M. Geleijnse, D. E. Grobbee, H. A. P. Pols, A. Hofman, J. C. M. 480 
Witteman and C. Vermeer, Nutritional intake of vitamins K1 (phylloquinone) and K2 481 
(menaquinone) in the netherlands, J. Nutr. Environ. Med., 1999, 9, 115-122. 482 
21 
 
12. X. Fu, X. Shen, E. G. Finnan, D. B. Haytowitz and S. L. Booth, Measurement of 483 
multiple vitamin K forms in processed and fresh-cut pork products in the U.S. food 484 
supply, J. Agric. Food Chem., 2016, 64, 4531-4535. 485 
13. USDA provisional table on the vitamin K contents in food, 486 
https://ndb.nal.usda.gov/ndb/nutrients/report/nutrientsfrm?max=25&offset=0&totCou487 
nt=0&nutrient1=430&nutrient2=428&nutrient3=&subset=0&sort=c&measureby=g, 488 
(accessed March 30, 2019). 489 
14. S. J. Elder, D. B. Haytowitz, J. Howe, J. W. Peterson and S. L. Booth, Vitamin K 490 
contents of meat, dairy, and fast food in the U.S. diet, J. Agric. Food Chem., 2006, 54, 491 
463-467. 492 
15. M. Kamao, Y. Suhara, N. Tsugawa, M. Uwano, N. Yamaguchi, K. Uenishi, H. Ishida, 493 
S. Sasaki and T. Okano, Vitamin K content of foods and dietary vitamin K intake in 494 
Japanese young women, J. Nutr. Sci. Vitaminol. (Tokyo), 2007, 53, 464-470. 495 
16. E. Manoury, K. Jourdon, P. Boyaval and P. Fourcassie, Quantitative measurement of 496 
vitamin K2 (menaquinones) in various fermented dairy products using a reliable high-497 
performance liquid chromatography method, J. Dairy Sci., 2013, 96, 1335-1346. 498 
17. X. Fu, S. G. Harshman, X. Shen, D. B. Haytowitz, J. P. Karl, B. E. Wolfe and S. L. 499 
Booth, Multiple vitamin K forms exist in dairy foods, Curr Dev Nutr, 2017, 1, DOI: 500 
10.3945/cdn.117.000638. 501 
18. J. W. J. Beulens, M. L. Bots, F. Atsma, M.-L. E. L. Bartelink, M. Prokop, J. M. 502 
Geleijnse, J. C. M. Witteman, D. E. Grobbee and Y. T. van Der Schouw, High dietary 503 
menaquinone intake is associated with reduced coronary calcification, 504 
Atherosclerosis, 2009, 203, 489-493. 505 
19. B. Holst and G. Williamson, Nutrients and phytochemicals: from bioavailability to 506 
bioefficacy beyond antioxidants, Curr. Opin. Biotechnol., 2008, 19, 73-82. 507 
20. J. Beulens, S. Booth, E. van Den Heuvel, E. Stoecklin, A. Baka and C. Vermeer, The 508 
role of menaquinones (vitamin K2) in human health, Br. J. Nutr., 2013, 110, 1357-509 
1368. 510 
21. S. L. Booth, A. H. Lichtenstein and G. E. Dallal, Phylloquinone absorption from 511 
phylloquinone-fortified oil is greater than from a vegetable in younger and older men 512 
and women, J. Nutr., 2002, 132, 2609-2612. 513 
22. A. K. Garber, N. C. Binkley, D. C. Krueger and J. W. Suttie, Comparison of 514 
phylloquinone bioavailability from food sources or a supplement in human subjects, 515 
J. Nutr., 1999, 129, 1201-1203. 516 
22 
 
23. L. J. Schurgers and C. Vermeer, Differential lipoprotein transport pathways of K-517 
vitamins in healthy subjects, Biochim. Biophys. Acta, 2002, 1570, 27-32. 518 
24. T. Sato, L. J. Schurgers and K. Uenishi, Comparison of menaquinone-4 and 519 
menaquinone-7 bioavailability in healthy women, Nutr. J., 2012, 11, 93. 520 
25. M. C. Barbara Walther, in Vitamin K2 - Vital for Health and Wellbeing, ed. J. O. 521 
Gordeladze, IntechOpen, 2017, DOI: 10.5772/63712. 522 
26. K. Nakagawa, Y. Hirota, N. Sawada, N. Yuge, M. Watanabe, Y. Uchino, N. Okuda, 523 
Y. Shimomura, Y. Suhara and T. Okano, Identification of UBIAD1 as a novel human 524 
menaquinone-4 biosynthetic enzyme, Nature, 2010, 468, 117-121. 525 
27. Y. Hirota, N. Tsugawa, K. Nakagawa, Y. Suhara, K. Tanaka, Y. Uchino, A. Takeuchi, 526 
N. Sawada, M. Kamao, A. Wada, T. Okitsu and T. Okano, Menadione (vitamin K3) is 527 
a catabolic product of oral phylloquinone (vitamin K1) in the intestine and a 528 
circulating precursor of tissue menaquinone-4 (vitamin K2) in rats, J. Biol. Chem., 529 
2013, 288, 33071-33080. 530 
28. M. J. Shearer, X. Fu and S. L. Booth, Vitamin K nutrition, metabolism, and 531 
requirements: current concepts and future research, Adv. Nutr., 2012, 3, 182-195. 532 
29. F. Fernandez and M. D. Collins, Vitamin K composition of anaerobic gut bacteria, 533 
FEMS Microbiol. Lett., 1987, 41, 175-180. 534 
30. M. D. Collins and D. Jones, Distribution of isoprenoid quinone structural types in 535 
bacteria and their taxonomic implication, Microbiol. Rev., 1981, 45, 316-354. 536 
31. M. J. Shearer and P. Newman, Metabolism and cell biology of vitamin K, Thromb. 537 
Haemost., 2008, 100, 530-547. 538 
32. J. M. Conly and K. Stein, Quantitative and qualitative measurements of K vitamins in 539 
human intestinal contents, Am. J. Gastroenterol., 1992, 87, 311-316. 540 
33. J. W. Suttie, The importance of menaquinones in human nutrition, Annu. Rev. Nutr., 541 
1995, 15, 399-417. 542 
34. H. K. Biesalski, Nutrition meets the microbiome: micronutrients and the microbiota, 543 
Ann. N. Y. Acad. Sci., 2016, 1372, 53-64. 544 
35. N. EFSA Panel on Dietetic Products, Allergies, D. Turck, J.-L. Bresson, B. 545 
Burlingame, T. Dean, S. Fairweather-Tait, M. Heinonen, K. I. Hirsch-Ernst, I. 546 
Mangelsdorf, H. J. McArdle, A. Naska, G. Nowicka, K. Pentieva, Y. Sanz, A. Siani, 547 
A. Sjödin, M. Stern, D. Tomé, H. Van Loveren, M. Vinceti, P. Willatts, C. Lamberg-548 
Allardt, H. Przyrembel, I. Tetens, C. Dumas, L. Fabiani, S. Ioannidou and M. 549 




36. Nutrient reference values for Australia and New Zealand: including recommended 552 
dietary intakes, Report 1864962372, National Health and Medical Research Council, 553 
Canberra, ACT, 2006. 554 
37. M. Vetrella and W. Barthelmai, Studies on drug-induced hemolysis: Effects of 555 
menadione and its water soluble preparations on the glutathione peroxidase of human 556 
erythrocytes, Klin. Wochenschr., 1972, 50, 234-238. 557 
38. N. C. Binkley, D. C. Krueger, T. N. Kawahara, J. A. Engelke, R. J. Chappell and J. 558 
W. Suttie, A high phylloquinone intake is required to achieve maximal osteocalcin 559 
gamma-carboxylation, Am. J. Clin. Nutr., 2002, 76, 1055-1060. 560 
39. S. Westenbrink and M. Jansen-van der Vliet, Dutch Food Composition Table, 561 
https://www.rivm.nl/en/dutch-food-composition-database, (accessed March 30, 2019). 562 
40. C. Vermeer, J. Raes, C. van 't Hoofd, M. H. J. Knapen and S. Xanthoulea, 563 
Menaquinone content of cheese, Nutrients, 2018, 10, DOI: 10.3390/nu10040446. 564 
41. Y. Zhang, W.-E. Zhou, J.-Q. Yan, M. Liu, Y. Zhou, X. Shen, Y.-L. Ma, X.-S. Feng, J. 565 
Yang and G.-H. Li, A Review of the extraction and determination methods of thirteen 566 
essential vitamins to the human body: An update from 2010, Molecules, 2018, 23, 567 
DOI: 10.3390/molecules23061484. 568 
42. Y. Zhang, V. Bala, Z. Mao, Y. S. Chhonker and D. J. Murry, A concise review of 569 
quantification methods for determination of vitamin K in various biological matrices, 570 
J. Pharm. Biomed. Anal., 2019, 169, 133-141. 571 
43. J. P. Karl, X. Fu, G. G. Dolnikowski, E. Saltzman and S. L. Booth, Quantification of 572 
phylloquinone and menaquinones in feces, serum, and food by high-performance 573 
liquid chromatography-mass spectrometry, J. Chromatogr. B Analyt. Technol. 574 
Biomed. Life Sci., 2014, 963, 128-133. 575 
44. G. G. Dolnikowski, Z. Sun, M. A. Grusak, J. W. Peterson and S. L. Booth, HPLC and 576 
GC/MS determination of deuterated vitamin K (phylloquinone) in human serum after 577 
ingestion of deuterium-labeled broccoli, J. Nutr. Biochem., 2002, 13, 168-174. 578 
45. K. S. Jones, L. J. Bluck and W. A. Coward, Analysis of isotope ratios in vitamin K1 579 
(phylloquinone) from human plasma by gas chromatography/mass spectrometry, 580 
Rapid Commun. Mass Spectrom., 2006, 20, 1894-1898. 581 
46. T. Koivu-Tikkanen, Determination of phylloquinone and menaquinones in foods by 582 
HPLC, University of Helsinki, 2001. 583 
24 
 
47. S. L. Booth and J. A. Sadowski, in Methods in Enzymology, Academic Press, 1997, 584 
Determination of phylloquinone in foods by high-performance liquid 585 
chromatography, 446-456. 586 
48. A. Gentili, A. Cafolla, T. Gasperi, S. Bellante, F. Caretti, R. Curini and V. P. 587 
Fernandez, Rapid, high performance method for the determination of vitamin K1, 588 
menaquinone-4 and vitamin K1 2,3-epoxide in human serum and plasma using liquid 589 
chromatography-hybrid quadrupole linear ion trap mass spectrometry, J. Chromatogr. 590 
A, 2014, 1338, 102-110. 591 
49. World Health Organisation, Cardiovascular diseases fact sheet, 2017. 592 
50. S. Mendis, P. Puska and B. Norrving, Global atlas on cardiovascular disease 593 
prevention and control, World Health Organisation, 2011. 594 
51. M. Abedin, Y. Tintut and L. Demer Linda, Vascular calcification, Arterioscler. 595 
Thromb. Vasc. Biol., 2004, 24, 1161-1170. 596 
52. M. K. Shea and R. M. Holden, Vitamin K status and vascular calcification: evidence 597 
from observational and clinical studies, Adv. Nutr., 2012, 3, 158-165. 598 
53. K. Sheng, P. Zhang, W. Lin, J. Cheng, J. Li and J. Chen, Association of matrix gla 599 
protein gene (rs1800801, rs1800802, rs4236) polymorphism with vascular 600 
calcification and atherosclerotic disease: a meta-analysis, Sci. Rep., 2017, 7, DOI: 601 
10.1038/s41598-017-09328-5. 602 
54. B. A. Willems, C. Vermeer, C. P. Reutelingsperger and L. J. Schurgers, The realm of 603 
vitamin K dependent proteins: shifting from coagulation toward calcification, Mol. 604 
Nutr. Food Res., 2014, 58, 1620-1635. 605 
55. J. Danziger, Vitamin K-dependent proteins, warfarin, and vascular calcification, Clin. 606 
J. Am. Soc. Nephrol., 2008, 3, 1504-1510. 607 
56. E. Theuwissen, E. Smit and C. Vermeer, The role of vitamin K in soft-tissue 608 
calcification, Adv. Nutr., 2012, 3, 166-173. 609 
57. H. Barrett, M. O'Keeffe, E. Kavanagh, M. Walsh and E. M. O'Connor, Is matrix gla 610 
protein associated with vascular calcification? a systematic review, Nutrients, 2018, 611 
10, DOI: 10.3390/nu10040415. 612 
58. J. H. Griffin, J. A. FernÁNdez, A. J. Gale and L. O. Mosnier, Activated protein C, J. 613 
Thromb. Haemost., 2007, 5, 73-80. 614 
59. S. L. Booth, A. Centi, S. R. Smith and C. Gundberg, The role of osteocalcin in human 615 
glucose metabolism: marker or mediator?, Nat. Rev. Endocrinol., 2013, 9, 43-55. 616 
25 
 
60. L. J. Schurgers, H. Aebert, C. Vermeer, B. Bültmann and J. Janzen, Oral 617 
anticoagulant treatment: friend or foe in cardiovascular disease?, Blood, 2004, 104, 618 
3231-3232. 619 
61. F. Violi, G. Y. Lip, P. Pignatelli and D. Pastori, Interaction between dietary vitamin K 620 
intake and anticoagulation by vitamin K antagonists: is it really true?: A systematic 621 
review, Medicine (Baltimore), 2016, 95, DOI: 10.1097/MD.0000000000002895. 622 
62. C. M. Schooling, Plasma levels of vitamin K and the risk of ischemic heart disease: a 623 
mendelian randomization study, J. Thromb. Haemost., 2016, 14, 1211-1215. 624 
63. G. Luo, P. Ducy, M. D. McKee, G. J. Pinero, E. Loyer, R. R. Behringer and G. 625 
Karsenty, Spontaneous calcification of arteries and cartilage in mice lacking matrix 626 
GLA protein, Nature, 1997, 386, 78-81. 627 
64. P. B. Munroe, R. O. Olgunturk, J.-P. Fryns, L. V. Maldergem, F. Ziereisen, B. 628 
Yuksel, R. M. Gardiner and E. Chung, Mutations in the gene encoding the human 629 
matrix gla protein cause keutel syndrome, Nat. Genet., 1999, 21, 142-144. 630 
65. M. Meier, L. P. Weng, E. Alexandrakis, J. Rüschoff and G. Goeckenjan, 631 
Tracheobronchial stenosis in keutel syndrome, Eur. Respir. J., 2001, 17, 566-569. 632 
66. S. M. Herrmann, C. Whatling, E. Brand, V. Nicaud, J. Gariepy, A. Simon, A. Evans, 633 
J. B. Ruidavets, D. Arveiler, G. Luc, L. Tiret, A. Henney and F. Cambien, 634 
Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, 635 
and myocardial infarction, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2386-2393. 636 
67. T. M. Miller, M. F. Abdel-Maksoud, L. A. Crane, A. C. Marcus and T. E. Byers, 637 
Effects of social approval bias on self-reported fruit and vegetable consumption: a 638 
randomized controlled trial, Nutr. J., 2008, 7, DOI: 10.1186/1475-2891-7-18. 639 
68. M. K. Shea and S. L. Booth, Concepts and controversies in evaluating vitamin K 640 
status in population-based studies, Nutrients, 2016, 8, DOI: 10.3390/nu8010008. 641 
69. J. M. Geleijnse, C. Vermeer, D. E. Grobbee, L. J. Schurgers, M. H. Knapen, I. M. van 642 
der Meer, A. Hofman and J. C. Witteman, Dietary intake of menaquinone is 643 
associated with a reduced risk of coronary heart disease: the rotterdam Study, J. Nutr., 644 
2004, 134, 3100-3105. 645 
70. S. R. Zwakenberg, A. I. P. Engelen, G. W. Dalmeijer, S. L. Booth, C. Vermeer, J. 646 
Drijvers, M. C. Ocke, E. J. M. Feskens, Y. T. van der Schouw and J. W. J. Beulens, 647 
Reproducibility and relative validity of a food frequency questionnaire to estimate 648 




71. G. C. M. Gast, N. M. de Roos, I. Sluijs, M. L. Bots, J. W. J. Beulens, J. M. Geleijnse, 651 
J. C. Witteman, D. E. Grobbee, P. H. M. Peeters and Y. T. van der Schouw, A high 652 
menaquinone intake reduces the incidence of coronary heart disease, Nutr., Metab. 653 
Cardiovasc. Dis., 2009, 19, 504-510. 654 
72. L. E. T. Vissers, G. W. Dalmeijer, J. M. A. Boer, W. M. M. Verschuren, Y. T. van 655 
Der Schouw and J. W. J. Beulens, The relationship between vitamin K and peripheral 656 
arterial disease, Atherosclerosis, 2016, 252, 15-20. 657 
73. S. R. Zwakenberg, N. R. den Braver, A. I. P. Engelen, E. J. M. Feskens, C. Vermeer, 658 
J. M. A. Boer, W. M. M. Verschuren, Y. T. van der Schouw and J. W. J. Beulens, 659 
Vitamin K intake and all-cause and cause specific mortality, Clin. Nutr., 2017, 36, 660 
1294-1300. 661 
74. L. E. T. Vissers, G. W. Dalmeijer, J. M. A. Boer, W. M. Monique Verschuren, Y. T. 662 
van Der Schouw and J. W. J. Beulens, Intake of dietary phylloquinone and 663 
menaquinones and risk of stroke, J. Am. Heart Assoc., 2013, 2, e000455. 664 
75. M. Juanola-Falgarona, J. Salas-Salvado, M. A. Martinez-Gonzalez, D. Corella, R. 665 
Estruch, E. Ros, M. Fito, F. Aros, E. Gomez-Gracia, M. Fiol, J. Lapetra, J. Basora, R. 666 
M. Lamuela-Raventos, L. Serra-Majem, X. Pinto, M. A. Munoz, V. Ruiz-Gutierrez, J. 667 
Fernandez-Ballart and M. Bullo, Dietary intake of vitamin K is inversely associated 668 
with mortality risk, J. Nutr., 2014, 144, 743-750. 669 
76. A. T. Erkkilä, S. L. Booth, F. B. Hu, P. F. Jacques, J. E. Manson, K. M. Rexrode, M. 670 
J. Stampfer and A. H. Lichtenstein, Phylloquinone intake as a marker for coronary 671 
heart disease risk but not stroke in women, Eur. J. Clin. Nutr., 2004, 59, 196. 672 
77. A. T. Erkkilä, S. L. Booth, F. B. Hu, P. F. Jacques and A. H. Lichtenstein, 673 
Phylloquinone intake and risk of cardiovascular diseases in men, Nutr., Metab. 674 
Cardiovasc. Dis., 2007, 17, 58-62. 675 
78. A. G. Mansour, E. Hariri, Y. Daaboul, S. Korjian, A. El Alam, A. D. Protogerou, H. 676 
Kilany, A. Karam, A. Stephan and S. A. Bahous, Vitamin K2 supplementation and 677 
arterial stiffness among renal transplant recipients—a single-arm, single-center 678 
clinical trial, J. Am. Soc. Hypertens., 2017, 11, 589-597. 679 
79. Y. Ikari, S. Torii, A. Shioi and T. Okano, Impact of menaquinone-4 supplementation 680 
on coronary artery calcification and arterial stiffness: an open label single arm study, 681 
Nutr. J., 2016, 15, DOI: 10.1186/s12937-016-0175-8. 682 
80. M. H. J. Knapen, L. A. J. L. M. Braam, N. E. Drummen, O. Bekers, A. P. G. Hoeks 683 
and C. Vermeer, Menaquinone-7 supplementation improves arterial stiffness in 684 
27 
 
healthy postmenopausal women. A double-blind randomised clinical trial, Thromb. 685 
Haemost., 2015, 113, 1135-1144. 686 
81. S. R. Zwakenberg, P. A. de Jong, J. W. Bartstra, R. van Asperen, J. Westerink, H. 687 
de Valk, R. H. J. A. Slart, G. Luurtsema, J. M. Wolterink, G. J. de Borst, J. A. 688 
van Herwaarden, M. A. van de Ree, L. J. Schurgers, Y. T. van der Schouw and J. W. 689 
J. Beulens, The effect of menaquinone-7 supplementation on vascular calcification in 690 
patients with diabetes: a randomized, double-blind, placebo-controlled trial, Am. J. 691 
Clin. Nutr., 2019, 110, 883-890. 692 
82. V. M. Brandenburg, S. Reinartz, N. Kaesler, T. Krüger, T. Dirrichs, R. Kramann, F. 693 
Peeters, J. Floege, A. Keszei and N. Marx, Slower progress of aortic valve 694 
calcification with vitamin K supplementation: results from a prospective 695 
interventional proof-of-concept study, Circulation, 2017, 135, 2081-2083. 696 
83. M. K. Shea, C. J. O'Donnell, U. Hoffmann, G. E. Dallal, B. Dawson-Hughes, J. M. 697 
Ordovas, P. A. Price, M. K. Williamson and S. L. Booth, Vitamin K supplementation 698 
and progression of coronary artery calcium in older men and women, Am. J. Clin. 699 
Nutr., 2009, 89, 1799-1807. 700 
84. L. A. J. L. M. Braam, A. P. G. Hoeks, F. Brouns, K. Hamulyák, M. J. W. 701 
Gerichhausen and C. Vermeer, Beneficial effects of vitamins D and K on the elastic 702 
properties of the vessel wall in postmenopausal women: a follow-up study, Thromb. 703 




Table 1: A compilation of commonly consumed foods that contain vitamin K1 and/or K2 obtained from a range of existing vitamin K resources. 706 
    Vitamin K content (µg/100 g or µg/100 ml )   
Type Food K1 MK4 MK5 MK6 MK7 MK8 MK9 MK10 MK11 MK12 MK13 Country
1 
Milk 
Full cream milk 0.5 0.8 0.1 UD UD UD UD UD - - - NL3 
Reduced fat milk 0.2 UD - - - - - - - - - USA13 
Soya milk 3.0 - - - - - - - - - - USA13 
Fats & Oils 
Margarine 93.2 UD UD UD UD UD UD UD - - - NL
3 
Butter 14.9 15 UD UD UD UD UD UD - - - NL
3 
Olive 53.7 UD UD UD UD UD UD UD - - - NL
3 
Butter & margarine blend 86.5 1.7 - - - - - - - - - USA13 
Canola 71.3 UD - - - - - - - - - USA
13 
Cheese 
Cheddar 2.4 9.5 UD 0.9 0.8 5.6 175 42.9 42.2 1.3 UD USA17 
Low fat cheddar 0.5 1.8 UD UD 0.7 4.0 22.6 1.5 16.3 UD UD USA17 
Cottage cheese 0.3 0.3 0.5 0.5 0.6 2.5 8 0.4 39.1 UD UD USA17 
Brie 4.9 12.5 UD UD UD UD UD UD - - - FRN40 
Camembert 2.5 8.0 1.3 0.1 3.2 1.5 4 UD - - - FRN40 
Parmesan 20.6 UD UD 0.01 0.1 0.2 UD UD - - - ITL40 
Cream cheese 2.4 UD - - - - - - - - - USA13 
Creams 
Yogurt (regular full-fat) 0.4 0.7 UD UD UD UD 13.2 1.6 8.4 UD UD USA17 
Standard full cream 2.4 9.3 UD UD UD UD 442 85.2 44.3  2.6   UD USA
17 
Ice cream 0.3 UD - - - - - - - - - USA13 
Breads 
White bread 3.4 - - - - - - - - - - USA
13 
Multigrain bread 1.5 - - - - - - - - - - USA
13 
Rye bread 0.7 UD UD UD UD UD UD UD - - - NL
3 
Meats 
Beef  0.02 1.4 UD UD 1.3 3.7 UD UD - - - NL40 
Minced Meat 1.1 7.6 UD UD UD UD UD UD - - - NL40 
Deer 2.4 0.9 UD UD UD UD UD UD - - - NL
40 




Pork UD 1.4 UD UD UD UD UD UD - - - NL
40 
Salmon 1.3 5.7 UD UD UD UD UD UD - - - NL
40 
Salami 2.3 9 UD UD UD UD UD UD - - - NL
40 
Goose liver 10.9 369 UD UD UD UD UD - - - - NL
40 
Egg yolk 2.1 31.4 UD 0.7 UD UD UD UD - - - NL
40 
Bacon 0.3 3 UD UD UD UD UD 2.0 29.7 UD UD USA17 
Lamb 4.5 UD - - - - - - - - - USA13 
Ham UD 4.3 - - - - - - - - - USA
13 
Pork sausage 0.3 18.3 - - - - - - - - - USA
13 
Tinned tuna (in water) 2.5 0 - - - - - - - - - USA
13 
Fruits 
Apples 3.0 UD UD UD UD UD UD UD - - - NL3 
Pears 5.2 - - - - - - - - - - USA13 
Avocardos 21 - - - - - - - - - - USA
13 
Vegetables 
Kale 817.0 UD UD UD UD UD UD UD - - - NL
3 
Broccoli 156.0 UD UD UD UD UD UD UD - - - NL
3 
Spinach 387.0 UD UD UD UD UD UD UD - - - NL
3 
Peas 36.0 UD UD UD UD UD UD UD - - - NL
3 
Cucumber 16.4 - - - - - - - - - - USA
13 
Lettuce (green) 126.3 - - - - - - - - - - USA
13 
Lettuce (red) 140.3 - - - - - - - - - - USA
13 
Celery 29.3 - - - - - - - - - - USA
13 
Carrots 13.2 - - - - - - - - - - USA
13 
Cabbage 76.0 - - - - - - - - - - USA
13 
Cauliflower 20.2 - - - - - - - - - - USA
13 
Potatoes 2.0 - - - - - - - - - - USA
13 
Tomatoes  7.9 - - - - - - - - - - USA
13 
Capsicum (green) 7.4 - - - - - - - - - - USA
13 
Zucchini 4.2 - - - - - - - - - - USA
13 




1 indicates origin of produce and/or country where vitamin K measurement was performed followed by reference. UD: undetected; -: unknown; USA: United States of 
America; NL: the Netherlands, JPN: Japan; FRN: France; ITY: Italy 
Cashews 34.1 - - - - - - - - - - USA
13 
Tofu (firm) 12.0 0.01 - - UD - - - - - - JPN15 
Fermented 
vegetables 
Natto 32.1 UD 7.2 12.4 996.5 82.4 UD UD - - - NL
40 
Saurkraut 22.4 0.4 0.9 1.6 0.2 0.9 1.5 UD - - - NL
40 
 707 
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